ArticlePloS one2021
Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Japanese clinical guidelines for neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2025Guideline
- Geometric and concavity characteristics as diagnostic markers for differentiating nAMD-related MNV from pachychoroid neovascularisation.Eye (London, England) · 2026Article
- Exploratory investigation of OCTA-VISTA for longitudinal monitoring of neovascular age-related macular degeneration treatment.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- The spectrum of pachychoroid neovasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Two-year outcomes of half-fluence photodynamic therapy combined with intravitreal aflibercept for treatment-naïve pachychoroid neovasculopathy.Japanese journal of ophthalmology · 2026Article
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Non-indocyanine green angiography non-invasive differentiating features in the differential diagnosis of pachychoroid neovasculopathy and neovascular age-related macular degeneration: a sensitivity-specificity study.Eye (London, England) · 2025Article
- Six-month outcomes of half-fluence photodynamic therapy combined with intravitreal Aflibercept injection for pachychoroid neovasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy.Scientific reports · 2025Article
- Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy.Scientific reports · 2025Article
- Review
- [Secondary choroidal neovascularization-Really so common?]Die Ophthalmologie · 2025Review
- The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration.Journal of clinical medicine · 2025Review
- Anatomical and Functional Outcomes of Anti-VEGF Therapy in Pachychoroid Neovasculopathy.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Importance of fluorescein angiography as a predictor of treatment response in patients with pachychoroid neovasculopathy.Scientific reports · 2024Article
- Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Observational
- Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy.Eye (London, England) · 2023Article
- Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multicenter retrospective study was conducted to evaluate the 1-year treatment outcome of photodynamic therapy (PDT) combined with anti-vascular endothelial growth factor (VEGF) therapy for pachychoroid neovasculopathy (PNV). A total of 42 eyes of 42 patients with treatment-naïve PNV who were treated with PDT combined with intravitreal injections of an anti-VEGF agent (ranibizumab or aflibercept) for 1 year. All eyes showed exudative and/or hemorrhagic changes that affected the fovea at baseline. After the initial combination therapy, subfoveal choroidal thickness (SCT) and central retinal thickness (CRT) were significantly reduced and were maintained as such for 12 months (P < 0.01 in SCT and CRT). The best-corrected visual acuity (BCVA) (0.19 ± 0.30 at baseline) significantly improved at 3 months (0.15 ± 0.29, P < 0.05) and further improved at 12 months (0.10 ± 0.30, P < 0.01) when compared to that at baseline. After the initial combination therapy, 32 eyes (76.2%) required no additional treatments for 12 months. The mean number of additional PDT and intravitreal injections of anti-VEGF agents was 0.1 ± 0.3 and 0.9 ± 1.9, respectively. Of the 42 eyes included in this study, 22 eyes (52.4%) had polypoidal lesions at baseline. No significant differences in SCT, CRT, or BCVA were observed at any time points between eyes with and without polypoidal lesions. Of 20 eyes without polypoidal lesions, only 1 eye (5.0%) needed additional treatments. PNV, especially without polypoidal lesions, can be treated effectively with PDT combined with anti-VEGF therapy with few sessions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.